Market Trends of Dilated Cardiomyopathy Therapeutic Industry
This section covers the major market trends shaping the Dilated Cardiomyopathy Therapeutic Market according to our research experts:
Angiotensin II receptor blockers is Expected to have a Significant Growth of the Market
Angiotensin II receptor blockers acquire a significant market share, followed by beta-blockers. This is attributed to the high demand for blockbuster drugs in dilated cardiomyopathy treatment, especially in developed regions. As per an article published by the National Library of Medicine in June 2022, the effects of angiotensin are lessened by angiotensin II receptor blockers (ARBs). High blood pressure is brought on by this protein's tendency to make blood vessels overly tight. ARBs also treat kidney disease and heart failure, as well as reduce the incidence of heart attacks and strokes. These factors are expected to drive and support segmental growth in the market.
Approval for this indication would further accelerate the overall sales of aldosterone antagonists, which would positively impact market growth. For instance, in September 2021, Otsuka Pharmaceutical Co., Ltd. announced that Novartis Pharma K.K. had obtained approval in Japan for ENTRESTO 100 mg and 200 mg Tablets for the new indication of hypertension. This approval is Japan's first ARNI for the indication of hypertension. The other driving factors of the segment are also related to the increasing prevalence of heart diseases. According to National Center for Chronic Disease Prevention and Health Promotion, Division for Heart Disease and Stroke Prevention, data updated in July 2022, 1 person dies every 34 seconds in the United States from cardiovascular disease. About 697,000 people in the United States died from heart disease in 2020, which is 1 in every 5 deaths. Hence, as the prevalence of heart diseases increases, the growth of the market increases too.
Therefore the above-mentioned factors are expected to drive segmental growth in the market.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall dilated cardiomyopathy therapeutics market, throughout the forecast period. The growth is due to the rising incidence of cardiovascular diseases, well-established insurance policies and the availability of advanced healthcare infrastructure are the major factors.
The United States holds the largest market share due to factors such as an increasing number of geriatric populations, along with a growing number of heart diseases in the country, which is anticipated to stimulate the demand in this region. According to American Heart Association, data updated in July 2022, The most prevalent kind, dilated cardiomyopathy (DCM), primarily affects adults under the age of 50. It affects the bottom and upper chambers of the heart, the ventricles, and the atria. The left ventricle, the heart's primary pumping chamber, is where the disease frequently develops first. The heart muscle starts to widen, stretch, and get thinner. The interior of the chamber therefore grows. The right ventricle is frequently affected before the atria. These factors are expected to promote the growth of the market in the region.
According to National Heart, Lung, and Blood Institute, data updated in March 2022, about 18.2 million American adults have coronary artery disease, making it the most common type of heart disease in the United States. Therefore as the number of cardiovascular diseases increases the market for dilated cardiomyopathy also increases.
Therefore, the above-mentioned factors are expected to drive the market in the region during the forecast period.
